Cargando…
Interpreting a Bayesian phase II futility clinical trial
BACKGROUND: A resurgence of research into phase II trial design in the mid-2000s led to the use of futility designs in a wide variety of disease areas. Phase II futility studies differ from efficacy studies in that their null hypothesis is that treatment, relative to control, does not meet or exceed...
Autores principales: | Beall, Jonathan, Cassarly, Christy, Martin, Renee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682669/ https://www.ncbi.nlm.nih.gov/pubmed/36414953 http://dx.doi.org/10.1186/s13063-022-06877-7 |
Ejemplares similares
-
Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial
por: Chen, Dung-Tsa, et al.
Publicado: (2019) -
Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility
por: Kimani, Peter K, et al.
Publicado: (2013) -
Speech Entrainment for Aphasia Recovery (SpARc) phase II trial design
por: Cassarly, Christy, et al.
Publicado: (2021) -
Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
por: Cassarly, Christy, et al.
Publicado: (2017) -
Determining a Bayesian predictive power stopping rule for futility in a non-inferiority trial with binary outcomes
por: Heath, Anna, et al.
Publicado: (2020)